{"url_path":"/sec/elvn/proxy/2026-04-27/000119312526182081","section_key":"body","section_title":"DEFA14A body","topic":"sec","document":{"doc_type":"DEFA14A","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-182081-index.html","accession_number":"0001193125-26-182081","cik":"0001672619","ticker":"ELVN","issuer_name":"Enliven Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-182081-index.html","primary_entity_key":"0001672619","primary_entity_name":"Enliven Therapeutics, Inc."},"word_count":783,"has_tables":true,"body_markdown":"DEFA14A\n1\nd948532ddefa14a.htm\nDEFA14A\n\nDEFA14A\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**SCHEDULE 14A**\n\n**PROXY STATEMENT PURSUANT\nTO SECTION 14(a) OF THE**\n\n**SECURITIES EXCHANGE ACT OF 1934**\n\nFiled by the Registrant ☒\n\nFiled by a Party other than the Registrant ☐\n\nCheck the appropriate box:\n\n☐\n\nPreliminary Proxy Statement\n\n☐\n\n**Confidential, for Use of the Commission Only (as permitted by Rule\n14a-6(e)(2))**\n\n☐\n\nDefinitive Proxy Statement\n\n☒\n\nDefinitive Additional Materials\n\n☐\n\nSoliciting Material Pursuant to §240.14a-12\n\n**Enliven Therapeutics, Inc.**\n\n**(Name of\nRegistrant as Specified In Its Charter)**\n\n**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**\n\nPayment of Filing Fee (Check all boxes that apply):\n\n☒\n\nNo fee required.\n\n☐\n\nFee paid previously with preliminary materials.\n\n☐\n\nFee computed on table below in exhibit required by Item 25(b) per Exchange Act Rules\n14a-6(i)(1) and 0-11.\n\nP.O. BOX 8016, CARY, NC 27512-9903\n\n**Enliven Therapeutics, Inc.**\n\n**Annual Meeting of Stockholders**\n\nTuesday, June 9, 2026 10:00 A. M., Mountain Time\n\nAnnual meeting to be held\nvirtually via the internet - please visit www.proxydocs.com/ELVN for more details.\n\n**You must\nregister to attend the meeting online and/or participate at www.proxydocs.com/ELVN**\n\n**For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting\ngo to www.proxydocs.com/ELVN**\n\n**To vote your proxy while visiting this site, you will\nneed the 12 digit control number in the box below.**\n\nThis communication is not a form for\nvoting and presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. You cannot use this notice to vote your shares. We encourage you to access and review\nall of the important information contained in the proxy materials before voting.\n\nUnder United\nStates Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.\n\nIf you want to receive a paper or e-mail copy of the proxy materials, you must request one. There\nis no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 29, 2026.\n\n \n\n**Meeting Materials:**Notice of Meeting and Proxy\nStatement & Annual Report or Form 10-K ****\n\n**Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 9, 2026 for\nstockholders of record as of April 10, 2026**\n\n**To order paper\nmaterials, use one of the following methods.**\n\n \n\n**Internet:**\n\n**www.investorelections.com/ELVN**\n\n \n\n**Call:**\n\n**1-866-648-8133**\n\n \n\n**Email:**\n\n**paper@investorelections.com**\n\n* If\nrequesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.\n\nHave the 12 digit control number located in the box above available when you access the website and follow the\ninstructions.\n\n**SEE REVERSE FOR FULL AGENDA**\n\nCopyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved\n\n**Enliven Therapeutics, Inc. Annual Meeting of Stockholders**\n\n**THE BOARD OF DIRECTORS RECOMMENDS A VOTE:**\n\n**FOR** the election of the two Class III directors\n\n**FOR**the ratification of\nthe appointment of Deloitte & Touche as our independent registered public accounting firm for fiscal year ending December 31, 2026\n\n**FOR**the amendment of\nour amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares\n\n**FOR**the approval, in an advisory (non-binding) vote, of the compensation of our named executive officers as disclosed in our proxy statement\n\nFor the approval, in an advisory (non-binding) vote, of the frequency of future stockholder advisory votes on the compensation of our named executive officers to be held\nevery **ONE YEAR**\n\n**PROPOSAL**\n\n1.\n\nTo elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation\nor removal.\n\n1.01 Richard Fair, M.B.A.\n\n1.02 Lori Kunkel, M.D.\n\n2.\n\nTo ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.\n\n3.\n\nTo amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.\n\n4.\n\nTo approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.\n\n5.\n\nTo approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.\n\n6.\n\nTo transact other business that may properly come before the Annual Meeting."}